Apogee Therapeutics Announces Agenda for Virtual R&D Day

Core Insights - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology (I&I) markets, including treatments for atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) [1][5] - The company will host a virtual R&D Day on December 2, 2024, to discuss its advancements and future strategies in the I&I space [1] Company Overview - Apogee Therapeutics aims to provide differentiated efficacy and dosing in the I&I markets, targeting conditions such as AD, asthma, and COPD [1][5] - The company’s lead program, APG777, is being developed for AD, which is identified as the largest and least penetrated market in I&I [5] - Apogee's antibody programs are designed to address limitations of existing therapies by targeting established mechanisms of action and utilizing advanced antibody engineering [5] R&D Day Agenda - The agenda includes discussions on Apogee's vision for next-gen biotech, interim results from the APG808 Phase 1 clinical trial, and updates on APG777 [4] - Key opinion leaders will present on topics such as the need for new treatment opportunities in I&I conditions and the potential of IL-13 + OX40L combination therapy for AD [2][4] - The event will also cover commercial opportunities and strategies, concluding with a Q&A session [4] Featured Speakers - Notable speakers include Emma Guttman-Yassky, M.D., Ph.D., and David Singh, M.D., who will provide insights into the current landscape of I&I treatments [2][3]